The Lancet· Biree Andemariam, Kevin H M Kuo, Farjah H Algahtani, Salam Al Kindi, Kenneth I Ataga, Pablo Bartolucci, Andrew Campbell, Raffaella Colombatti, Alexander K Glaros, Kaoutar Hafraoui, Modupe Idowu, Seethal A Jacob, Clarisse L C Lobo, Obiageli E Nnodu, Lucas Otieno, Wally R Smith, Swee Lay Thein, Eduard J van Beers, Sarah Gheuens, Brooke Hensley, Abdulafeez Oluyadi, Kareem Osman, Asif Pathan, Spurthi Patil, Tao Song, Amber M Yates, Ahmar U Zaidi, Caterina Minniti, Miguel R Abboud, RISE UP Investigators·· 26 天前精选AI 评分72
mitapivat治疗镰状细胞病的III期RISE UP试验:疗效与安全性结果
[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial
AI 导读
RISE UP是一项全球、双盲、随机、安慰剂对照的III期试验,评估口服丙酮酸激酶激活剂mitapivat在镰状细胞病患者中的疗效与安全性。mitapivat通过改善溶血性贫血这一新机制,有望成为有效且便捷的疾病修饰治疗。
推荐理由
这项全球III期试验给出mitapivat在镰状细胞病中的疗效与安全性数据,可供评估口服丙酮酸激酶激活剂的治疗位置。
来源:The Lancet · thelancet.com